Bookstore

Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle.

Handbook of Therapeutic Antibodies, 4 Vols.

VOLUME I: DEFINING THE RIGHT ANTIBODY COMPOSITIONTherapeutic Antibodies - From Past to Future (Stefan Dübel)PART 1: SELECTING AND SHAPING THE ANTIBODY MOLECULESelection Strategies I: Monoclonal Antibodies (Gerhard Moldenhauer)Selection Strategies II: Antibody Phage Display (Michael Hust, Andre Frenzel, Florian Tomszak, Jonas Köller)Transgenic Animals Derived by DNA Microinjection (Marianne Brüggemann, Michael J. Osborn, Biao Moa, Suzanne Avis, Ignacio Anegon, Roland Bülow)Molecular Engineering I: Humanisation Strategies (Jose Saldanha)Antibody Affinity (Andre Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, Larry Green)Molecular Engineering III: Fc (Thomas Valerius, Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner)Glycosylation of Antibody Molecules (Roy Jefferis)Bioinformatics Tools for Analysis of Antibodies (Andrew C. R. Martin, James Allen)How to use IMGT for Therapeutic Antibody Engineering (Marie-Paul Lefranc)PART 2: MODIFIED ANTIBODIESBispecific Antibodies (Roland E. Kontermann, Dafne Müller)Single Domain Antibodies: An Overview (Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, B. Hamilton)Antibody-Drug Conjugates (ADCs): New Frontier in Cancer Therapeutics (Ravi Chari, Rajeeva Singh, John M. Lambert)Antibody Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins (Jürgen Krauss, Athanasios Mavratzas, Michaela A. E. Arndt, Stefan Kiesgen)PART 3: EMERGING TECHNOLOGIESEmerging Technologies for Antibody Selection (Mike Taussig, Mingyue He)Anti-idiotypic Antibodies (Alejandro Lopez-Requena, Oscar Roberto Burrone, Rolando Perez)Non-antibody Scaffolds as Alternative Therapeutic Agents (Arne Skerra, Markus Fiedler)Antibody Directed Enzyme Prodrug Therapy (ADEPT) (Surinder K. Sharma, Kerry A. Chester, Kenneth D. Bagshawe)Engineered Antibody Domains as Candidate Therapeutics (Weizao Chen, Ponraj Prabakaran, Dimiter S. Dimitrov)Chimeric Antigen Receptors - "CARs" (Thomas Schirrmann, Ulf Petrausch)Emerging Alternative Production Systems (Thomas Jostock, Benjamin Sommer, Holger Laux, Andre Frenzel)VOLUME II: CLINICAL DEVELOPMENT OF ANTIBODIESPART 4: THE WAY INTO THE CLINICProcess Development and Manufacturing of Therapeutic Antibodies (Hitto Kaufmann, Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser)The Immunogenicity of Therapeutic Antibodies (Melody Sauerborn)Biosimilar Monoclonal Antibodies (Susanne D. Pippig, Carsten Brockmeyer, Robert E. Zoubek)Patent Issues Relating to Therapeutic Antibodies (Michael Braunagel, Barbara Rigby, Deborah Owen)PART 5: THERAPEUTIC ANTIBODY PIPELINEMonoclonal Antibodies in Phase III Clinical Trials (Peter Markus Deckert, Ulf Petrausch)Antibodies in Early Phase Clinical Studies: Cancer Therapy (Anthony Olszanski, Matthew Zibelman, Hossein Borghaei)Targeting Angiogenesis by Therapeutic Antibodies (Thomas Effert, Onat Kadioglu, Ean Jeong Seo)Antibodies in Phase 3: Immunological Disorders (Penelope Ward, Mark Bodmer)Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders (Frank Brennan)MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders (Frank Brennan)T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan)B Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan)Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan)Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan)IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan)Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan)mAbs Targeting Apoptosis, Angiogenesis Inhibitors and other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders (Fr